French healthcare platform Alan, cofounded by Jean-Charles Samuelian-Werve and Charles Gorintin, announced today that it has raised a €185M Series D which puts the company in the unicorn club, at a €1.4 billion valuation.
Category Archive: /under30
Biotech R&D Startup Benchling Hits $4 Billion Valuation As The Company Starts Laying Groundwork For An IPO
Sajith Wickramasekara was just 24 when he got on Forbes 30 Under 30 list for his biotech R&D startup Benchling. Now his company is worth $4 billion with a new $200 million round led by Sequoia.
30 Under 30 Europe 2021: Changing The World From Artificial Intelligence To Covid-19
These healthcare and science listmakers are inventing the future from the atom up.
Healthcare’s Latest Unicorn: Big Data Startup Innovaccer Raises $105 Million At $1.3 Billion Valuation
On the heels of a year that saw a record amount of venture cash flow into healthcare startups, investor appetite for healthtech does not appear to be waning.
Researchers Estimate There Were 17 Million Undiagnosed Cases Of Covid-19 Last Summer
A new preprint from the National Institutes of Health found that almost 5% of American adults had undiagnosed Covid-19.
30 Under 30 In Healthcare 2021: Fighting Covid, Mental Illness And Health Inequities
This exceptional group of entrepreneurs, researchers and clinicians are working to solve some of the most pressing healthcare challenges.
On The Frontlines: Here’s How This Year’s 30 Under 30 Is Combating The Coronavirus
These 2021 30 Under 30 listmakers from the science and healthcare lists have devoted time, energy, and countless research hours to helping solve the Covid-19 crisis
Inside Ritual’s Katerina Schneider’s Plan To Build A Better Multivitamin
By betting on a subscription business model and targeting niche groups like expectant moms and teen girls, can this former venture partner crack the $36 billion vitamin and supplement industry?
Survivors & Thrivers
Amid a pandemic implosion, these startups showcase the strength, diversity and adaptability of America’s entrepreneurs—and provide hope for the country’s economic future.
Mammoth Biosciences Signs Exclusive Deal For Recently-Discovered Crispr Protein
Biotech company Mammoth Biosciences has signed an exclusive deal with University of California Berkeley to license a newly-discovered class of Crispr proteins.
